⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93299 | 1.00 | — | — | |
| SCHEMBL2556475 | 1.00 | — | — | |
| Ethylene SCHEMBL10802720 | 0.93 | — | — | |
| Oxirane SCHEMBL10796207 | 0.90 | — | — | |
| Propylene Oxide SCHEMBL10792620 | 0.87 | — | — | |
| SCHEMBL18652809 | 0.76 | — | — | |
| SCHEMBL8347293 | 0.72 | — | — | |
| SCHEMBL1703680 | 0.72 | — | — | |
| SCHEMBL7527882 | 0.67 | — | — | |
| SCHEMBL7524613 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624033-B2 | KRAS inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735440-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250250271-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250154148-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-15 | — | — | US | disclosed |
| WO-2025006962-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-2890672-B1 | PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS | NOVARTIS AG (CH) | 2018-05-30 | — | — | EP | disclosed |
| US-9624163-B2 | Process for preparing intermediates useful in the manufacture of NEP inhibitors | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9175013-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20150210632-A1 | NEW PROCESS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140179690-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| CN-103459401-A | Fused aminodihydrothiazine derivatives | EISAI R&D MAN CO LTD | 2013-12-18 | — | — | CN | disclosed |
| EP-2665731-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012098461-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | WO | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |